Pharmacogenetics: From Bench to Byte-An Update of Guidelines

JJ Swen; Marien Nijenhuis; A den Boer; L Grandia; AH Zee; H Mulder; GAPJM Rongen; Ron van Schaik; T Schalekamp; DJ Touw; J van der Weide; B Wilffert; VHM Deneer; HJ Guchelaar

doi:10.1038/clpt.2011.34

Pharmacogenetics: From Bench to Byte-An Update of Guidelines

JJ Swen, Marien Nijenhuis, A den Boer, L Grandia, AH Zee, H Mulder, GAPJM Rongen, Ron van Schaik, T Schalekamp, DJ Touw, J van der Weide, B Wilffert, VHM Deneer, HJ Guchelaar

Research output: Contribution to journal › Article › Academic › peer-review

859 Citations (Scopus)

Abstract

Currently, there are very few guidelines linking the results of pharmacogenetic tests to specific therapeutic recommendations. Therefore, the Royal Dutch Association for the Advancement of Pharmacy established the Pharmacogenetics Working Group with the objective of developing pharmacogenetics-based therapeutic (dose) recommendations. After systematic review of the literature, recommendations were developed for 53 drugs associated with genes coding for CYP2D6, CYP2C19, CYP2C9, thiopurine-S-methyltransferase (TPMT), dihydropyrimidine dehydrogenase (DPD), vitamin K epoxide reductase (VKORC1), uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1), HLA-B44, HLA-B*5701, CYP3A5, and factor V Leiden (FVL).

Original language	Undefined/Unknown
Pages (from-to)	662-673
Number of pages	12
Journal	Clinical Pharmacology & Therapeutics
Volume	89
Issue number	5
DOIs	https://doi.org/10.1038/clpt.2011.34
Publication status	Published - 2011

Research programs

EMC MM-01-25-01

Access to Document

10.1038/clpt.2011.34

http://hdl.handle.net/1765/25853

Cite this

@article{9fa30e89b5a54c8299f29824feb67f3a,

title = "Pharmacogenetics: From Bench to Byte-An Update of Guidelines",

abstract = "Currently, there are very few guidelines linking the results of pharmacogenetic tests to specific therapeutic recommendations. Therefore, the Royal Dutch Association for the Advancement of Pharmacy established the Pharmacogenetics Working Group with the objective of developing pharmacogenetics-based therapeutic (dose) recommendations. After systematic review of the literature, recommendations were developed for 53 drugs associated with genes coding for CYP2D6, CYP2C19, CYP2C9, thiopurine-S-methyltransferase (TPMT), dihydropyrimidine dehydrogenase (DPD), vitamin K epoxide reductase (VKORC1), uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1), HLA-B44, HLA-B*5701, CYP3A5, and factor V Leiden (FVL).",

author = "JJ Swen and Marien Nijenhuis and {den Boer}, A and L Grandia and AH Zee and H Mulder and GAPJM Rongen and {van Schaik}, Ron and T Schalekamp and DJ Touw and {van der Weide}, J and B Wilffert and VHM Deneer and HJ Guchelaar",

year = "2011",

doi = "10.1038/clpt.2011.34",

language = "Undefined/Unknown",

volume = "89",

pages = "662--673",

journal = "Clinical Pharmacology & Therapeutics",

issn = "0009-9236",

publisher = "Wiley-Blackwell",

number = "5",

}

TY - JOUR

T1 - Pharmacogenetics: From Bench to Byte-An Update of Guidelines

AU - Swen, JJ

AU - Nijenhuis, Marien

AU - den Boer, A

AU - Grandia, L

AU - Zee, AH

AU - Mulder, H

AU - Rongen, GAPJM

AU - van Schaik, Ron

AU - Schalekamp, T

AU - Touw, DJ

AU - van der Weide, J

AU - Wilffert, B

AU - Deneer, VHM

AU - Guchelaar, HJ

PY - 2011

Y1 - 2011

N2 - Currently, there are very few guidelines linking the results of pharmacogenetic tests to specific therapeutic recommendations. Therefore, the Royal Dutch Association for the Advancement of Pharmacy established the Pharmacogenetics Working Group with the objective of developing pharmacogenetics-based therapeutic (dose) recommendations. After systematic review of the literature, recommendations were developed for 53 drugs associated with genes coding for CYP2D6, CYP2C19, CYP2C9, thiopurine-S-methyltransferase (TPMT), dihydropyrimidine dehydrogenase (DPD), vitamin K epoxide reductase (VKORC1), uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1), HLA-B44, HLA-B*5701, CYP3A5, and factor V Leiden (FVL).

AB - Currently, there are very few guidelines linking the results of pharmacogenetic tests to specific therapeutic recommendations. Therefore, the Royal Dutch Association for the Advancement of Pharmacy established the Pharmacogenetics Working Group with the objective of developing pharmacogenetics-based therapeutic (dose) recommendations. After systematic review of the literature, recommendations were developed for 53 drugs associated with genes coding for CYP2D6, CYP2C19, CYP2C9, thiopurine-S-methyltransferase (TPMT), dihydropyrimidine dehydrogenase (DPD), vitamin K epoxide reductase (VKORC1), uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1), HLA-B44, HLA-B*5701, CYP3A5, and factor V Leiden (FVL).

U2 - 10.1038/clpt.2011.34

DO - 10.1038/clpt.2011.34

M3 - Article

C2 - 21412232

SN - 0009-9236

VL - 89

SP - 662

EP - 673

JO - Clinical Pharmacology & Therapeutics

JF - Clinical Pharmacology & Therapeutics

IS - 5

ER -